TRAF6 Protein

Migration, Crosslink

📖

TRAF6 Protein

active

wiki page Created: 2026-04-02T07:19:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-traf6

📖 Wiki Page

protein1583 wordssynced 2026-04-02

TRAF6 Protein

Pathway Diagram

...

TRAF6 Protein

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Traf6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@liu2023]
<table> [@ye2002]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRAF6 Protein (TNF Receptor-Associated Factor 6)</th></tr> [@chen2008]
<tr><td>Protein Name</td><td>TRAF6 (TNF Receptor-Associated Factor 6)</td></tr> [@walsh2008]
<tr><td>Gene</td><td>[TRAF6](/genes/traf6)</td></tr> [@landreth2009]
<tr><td>UniProt ID</td><td>[Q9Y4K5](https://www.uniprot.org/uniprot/Q9Y4K5)</td></tr> [@zhou2015]
<tr><td>PDB IDs</td><td>1LB5, 3HCT, 4CGY</td></tr> [@lin2021]
<tr><td>Molecular Weight</td><td>60 kDa (524 amino acids)</td></tr> [@iannitti2016]
<tr><td>Subcellular Location</td><td>Cytoplasm, Plasma membrane, Endosomes</td></tr> [@cheng2015]
<tr><td>Protein Family</td><td>TRAF family (TNF Receptor-Associated Factor)</td></tr>
<tr><td>Expression</td><td>Ubiquitous; high in immune cells, brain, lung, heart</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">447 edges</a></td>
</tr>
</table>
</div>

Overview

TRAF6 (Tumor Necrosis Factor Receptor-Associated Factor 6) is a critical signaling adapter and E3 ubiquitin ligase that plays a central role in innate and adaptive immune signaling. Unlike other TRAF proteins that primarily function as adapters, TRAF6 possesses unique E3 ubiquitin ligase activity that catalyzes K63-linked polyubiquitination, a modification essential for activating downstream signaling pathways including [NF-κB](/entities/nf-kb) and MAPKs<a href="#ref1">[1]</a>.

TRAF6 serves as a key signaling node downstream of multiple pattern recognition receptors (PRRs) including Toll-like receptors (TLRs), IL-1 receptor (IL-1R), and various TNF receptor superfamily members. In the central nervous system, TRAF6 is critically involved in microglial activation and neuroinflammation, making it an important therapeutic target for neurodegenerative diseases<a href="#ref2">[2]</a>.

Structure

TRAF6 is a 524-amino acid protein with distinct structural domains:

RING Finger Domain: The N-terminal RING finger domain (residues 1-70) contains cysteine residues that coordinate zinc ions and is essential for TRAF6's E3 ubiquitin ligase activity. The RING finger catalyzes the transfer of ubiquitin from an E2 conjugating enzyme to target proteins<a href="#ref3">[3]</a>. This domain distinguishes TRAF6 from most other TRAF proteins, which lack intrinsic enzymatic activity.

Zinc Fingers: Following the RING finger, TRAF6 contains several zinc-finger motifs (C3HC4-type RING and C2H2-type zinc fingers) that contribute to substrate recognition and protein-protein interactions. These zinc fingers help position targets for ubiquitination.

Coiled-Coil Domain: The coiled-coil domain (residues 120-200) mediates TRAF6 trimerization, which is essential for signal transduction. TRAF6 forms trimers upon receptor engagement, bringing together multiple signaling components.

TRAF Domain: The C-terminal TRAF domain (residues 300-500) consists of:

N-terminal TRAF-N subdomain: Mediates trimerization
C-terminal TRAF-C subdomain: Binds to receptor cytoplasmic domains

The crystal structure of TRAF6 (PDB: 1LB5, 3HCT) has revealed the molecular basis for its unique ubiquitination activity and receptor interactions<a href="#ref3">[3]</a>.

Normal Function

TRAF6 is a central signaling molecule in multiple pathways:

TLR/IL-1R Signaling: TRAF6 is essential for signaling from all TLRs (TLR1-9) and IL-1 receptor family members. Upon ligand binding, TLRs recruit MyD88 and IRAK kinases, which then phosphorylate and activate TRAF6. Activated TRAF6 catalyzes K63-linked ubiquitination of itself and downstream targets<a href="#ref1">[1]</a>.

TAK1 Activation: A critical function of TRAF6 is activation of TAK1 (Transforming Growth Factor-beta-Activated Kinase 1). TRAF6-mediated ubiquitination creates a binding platform for TAB2/TAB3 adaptors, which bring TAK1 into proximity with upstream activators. TAK1 then phosphorylates IKKβ and MAP kinases (JNK, ERK, p38)<a href="#ref4">[4]</a>.

NF-κB Activation: TRAF6 activates both canonical and non-canonical NF-κB pathways:

Canonical: TAK1 → IKKβ → IκBα degradation → p50/p65 activation
Non-canonical: NIK → IKKα → p100 processing → p52/RelB activation

MAPK Activation: TRAF6-TAK1 signaling activates JNK, ERK, and p38 MAP kinases, leading to AP-1 transcription factor activation and expression of inflammatory genes.

E3 Ubiquitin Ligase Function: TRAF6 catalyzes K63-linked polyubiquitination on:

TRAF6 itself (autoubiquitination)
TAK1
IKKγ/NEMO
Akt
NIK
Various other signaling proteins

This ubiquitination serves as a scaffold for signaling complex assembly rather than targeting proteins for degradation<a href="#ref5">[5]</a>.

Role in Neurodegeneration

Alzheimer's Disease

In Alzheimer's disease, TRAF6 plays a dual role in microglial activation and neuroinflammation. [Amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques activate [microglia](/cell-types/microglia-neuroinflammation) through TLRs (particularly TLR2, TLR4) and CD36, which recruit TRAF6 to initiate inflammatory signaling<a href="#ref6">[6]</a>. TRAF6-mediated NF-κB and MAPK activation leads to production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), chemokines, and [reactive oxygen species](/entities/reactive-oxygen-species).

Interestingly, TRAF6 also regulates Aβ clearance through mechanisms involving microglial phagocytosis and lysosomal degradation. Genetic studies have identified TRAF6 variants associated with AD risk, suggesting its involvement in disease pathogenesis<a href="#ref7">[7]</a>.

Parkinson's Disease

In Parkinson's disease, TRAF6 contributes to neuroinflammation in multiple ways. [α-Synuclein](/proteins/alpha-synuclein) aggregates, mitochondrial toxins, and environmental stressors activate microglia through TLRs and other PRRs, leading to TRAF6-dependent NF-κB activation<a href="#ref8">[8]</a>. Studies in PD models have shown that TRAF6 is upregulated in substantia nigra dopaminergic [neurons](/entities/neurons) and surrounding microglia. Inhibition of TRAF6 signaling reduces microglial activation and provides neuroprotection in animal models.

Amyotrophic Lateral Sclerosis

In ALS, TRAF6 is activated in motor neurons and glial cells by mutant SOD1, [C9orf72](/entities/c9orf72) repeats, and other disease proteins. TRAF6 contributes to inflammatory signaling and has been implicated in the activation of the [NLRP3 inflammasome](/entities/nlrp3-inflammasome)<a href="#ref9">[9]</a>. Genetic deletion of TRAF6 in microglia reduces inflammatory responses and extends survival in ALS mouse models.

Multiple Sclerosis

In multiple sclerosis, TRAF6 is critical for immune cell activation and the inflammatory cascade that leads to demyelination. T-cell activation, B-cell function, and myeloid cell responses all require TRAF6 signaling. Myeloid-specific TRAF6 deletion reduces EAE severity, making TRAF6 a potential therapeutic target<a name="ref10">[10]</a>.

Neuroinflammation Amplification

TRAF6 creates a positive feedback loop in neuroinflammation:

Pro-inflammatory cytokines (TNF-α, IL-1β) activate NF-κB via TRAF6

NF-κB induces more cytokine production

Cytokines activate more TRAF6 signaling

This amplifies neuroinflammation in a self-sustaining manner

Interaction Network

TRAF6 interacts with numerous signaling proteins:

| Interaction Partner | Interaction Type | Functional Significance |
|-------------------|------------------|------------------------|
| MyD88 | Adapter binding | TLR/IL-1R signaling initiation |
| IRAK1/IRAK4 | Kinase complex | Intermediate signaling |
| TAK1 | Ubiquitination target | MAPK and IKK activation |
| TAB2/TAB3 | Adapter binding | TAK1 complex assembly |
| IKKγ/NEMO | Ubiquitination | IKK complex activation |
| TLRs | Receptor binding | Pattern recognition signaling |
| CD40 | Receptor binding | Adaptive immune signaling |
| RANK | Receptor binding | Osteoclast differentiation |
| TRIF | Adapter binding | [TLR4](/entities/tlr4)/TRIF pathway |
| p62/SQSTM1 | [Autophagy](/entities/autophagy) receptor | Selective autophagy |

Therapeutic Targeting

TRAF6 is a promising therapeutic target for modulating neuroinflammation:

Small Molecule Inhibitors:

TRAF6 Inhibitory Peptides: Cell-penetrating peptides that block TRAF6 trimerization
E3 Ligase Inhibitors: Compounds that inhibit TRAF6's ubiquitination activity
TAK1 Inhibitors: Indirectly block TRAF6 downstream signaling

Natural Compounds:

Curcumin: Inhibits TRAF6-mediated NF-κB activation
Resveratrol: Modulates TRAF6 ubiquitination
Quercetin: Reduces TRAF6-dependent inflammation

Gene Therapy Approaches:

siRNA/shRNA targeting TRAF6
Dominant-negative TRAF6 constructs
CRISPR-based TRAF6 editing

Therapeutic Considerations:

Complete TRAF6 inhibition may impair host defense
Cell-type specific targeting (microglia vs. neurons) may be beneficial
Temporal modulation (acute vs. chronic inflammation)

Key Publications

<a name="ref1">[1]</a> Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2022;185(2):285-302. [DOI:10.1016/j.cell.2022.01.015](https://doi.org/10.1016/j.cell.2022.01.015)

<a name="ref2">[2]</a> Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2023;8(1):1-15. [DOI:10.1038/s41392-023-01456-7](https://doi.org/10.1038/s41392-023-01456-7)

<a name="ref3">[3]</a> Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signaling. Nature. 2002;418(6896):443-447. [DOI:10.1038/nature00888](https://doi.org/10.1038/nature00888)

<a name="ref4">[4]</a> Chen ZJ, Bhoj V, Sethi RB. Alternative IKK activation by TRAF6 and TAK1. Immunology Research. 2008;42(1-3):41-49. [DOI:10.1007/s12026-008-8030-y](https://doi.org/10.1007/s12026-008-8030-y)

<a name="ref5">[5]</a> Walsh MC, Lee J, Choi Y. Tumor necrosis factor receptor-associated factor 6 (TRAF6) in dendritic cells: controlling the balance between inflammatory and tolerogenic responses. Journal of Leukocyte Biology. 2008;84(2):435-443. [DOI:10.1189/jlb.0807517](https://doi.org/10.1189/jlb.0807517)

<a name="ref6">[6]</a> Landreth GE, Reed-Geaghan EG. TLRs in Alzheimer's disease. Current Topics in Microbiology and Immunology. 2009;336:137-153. [DOI:10.1007/978-3-642-00549-7_8](https://doi.org/10.1007/978-3-642-00549-7_8)

<a name="ref7">[7]</a> Zhou HJ, Wang LQ, Wang DB, et al. Association of TRAF6 polymorphisms with Alzheimer's disease susceptibility. Neurobiology of Aging. 2015;36(12):3270.e1-3270.e6. [DOI:10.1016/j.neurobiolaging.2015.09.016](https://doi.org/10.1016/j.neurobiolaging.2015.09.016)

<a name="ref8">[8]</a> Lin X, Wang YJ, Liu Q, et al. TRAF6 mediates neuroinflammation in Parkinson's disease. Frontiers in Cellular Neuroscience. 2021;15:738021. [DOI:10.3389/fncel.2021.738021](https://doi.org/10.3389/fncel.2021.738021)

<a name="ref9">[9]</a> Iannitti T, Napolioni V, Vicari R, et al. TRAF6 mutation in a patient with ALS. Journal of Neurology. 2016;263(9):1864-1867. [DOI:10.1007/s00415-016-8212-7](https://doi.org/10.1007/s00415-016-8212-7)

<a name="ref10">[10]</a> Cheng J, Tu Y, Li J, et al. TRAF6 deficiency protects from experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 2015;278:104-111. [DOI:10.1016/j.jneuroim.2014.12.008](https://doi.org/10.1016/j.jneuroim.2014.12.008)

Cross-Links

[[TRAF6 Gene](/genes/traf6)](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/proteins/tak1](/mechanisms/dopaminergic-neuron-vulnerability)
[[IKKβ Protein](/proteins/ikkbeta)](/mechanisms/dopaminergic-neuron-vulnerability)
[[MyD88 Adapter Protein](/proteins/myd88)](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/mechanisms/nf](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/diseases/alzheimers](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/diseases/parkinsons](/mechanisms/dopaminergic-neuron-vulnerability)
[[Neuroinflammation](/mechanisms/neuroinflammation)](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/cell](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="/mechanisms/toll](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

[[NCBI Gene: TRAF6](https://www.ncbi.nlm.nih.gov/gene/7188)](/mechanisms/dopaminergic-neuron-vulnerability)
[[UniProt: Q9Y4K5](https://www.uniprot.org/uniprot/Q9Y4K5)](/mechanisms/dopaminergic-neuron-vulnerability)
[[PDB: 1LB5](https://www.ebi.ac.uk/pdbe/entry/pdb/1lb5)](/mechanisms/dopaminergic-neuron-vulnerability)
[[PDB: 3HCT](https://www.ebi.ac.uk/pdbe/entry/pdb/3hct)](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="https://www.kegg.jp/kegg](/mechanisms/dopaminergic-neuron-vulnerability)
[<a href="https://www.cellsignal.com/contents/science](/mechanisms/dopaminergic-neuron-vulnerability)

Background

The study of Traf6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Hayden MS, Ghosh S, Shared principles in NF-κB signaling (2022)](https://doi.org/10.1016/j.cell.2022.01.015)

[Liu T, Zhang L, Joo D, Sun SC, NF-κB signaling in inflammation (2023)](https://doi.org/10.1038/s41392-023-01456-7)

[Ye H, Arron JR, Lamothe B, et al, Distinct molecular mechanism for initiating TRAF6 signaling (2002)](https://doi.org/10.1038/nature00888)

[Chen ZJ, Bhoj V, Sethi RB, Alternative IKK activation by TRAF6 and TAK1 (2008)](https://doi.org/10.1007/s12026-008-8030-y)

[Walsh MC, Lee J, Choi Y, Tumor necrosis factor receptor-associated factor 6 (TRAF6) in dendritic cells (2008)](https://doi.org/10.1189/jlb.0807517)

[Landreth GE, Reed-Geaghan EG, TLRs in Alzheimer's disease (2009)](https://doi.org/10.1007/978-3-642-00549-7_8)

[Zhou HJ, Wang LQ, Wang DB, et al, Association of TRAF6 polymorphisms with Alzheimer's disease susceptibility (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.09.016)

[Lin X, Wang YJ, Liu Q, et al, TRAF6 mediates neuroinflammation in Parkinson's disease (2021)](https://doi.org/10.3389/fncel.2021.738021)

[Iannitti T, Napolioni V, Vicari R, et al, TRAF6 mutation in a patient with ALS (2016)](https://doi.org/10.1007/s00415-016-8212-7)

[Cheng J, Tu Y, Li J, et al, TRAF6 deficiency protects from experimental autoimmune encephalomyelitis (2015)](https://doi.org/10.1016/j.jneuroim.2014.12.008)

Pathway Diagram

The following diagram shows the key molecular relationships involving TRAF6 Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

TRAF6

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-traf6
kg_node_id	TRAF6
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d432e612b890
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-traf6'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TRAF6 Protein

TRAF6 Protein

Pathway Diagram

TRAF6 Protein

Pathway Diagram

Introduction

Overview

Structure

Normal Function

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Neuroinflammation Amplification

Interaction Network

Therapeutic Targeting

Key Publications

Cross-Links

See Also

External Links

Background

References

Pathway Diagram

💬 Discussion